HALO Stock Analysis: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$69.61
0.62 (0.90%)
▲
5d:
-2.34%
30d:
+1.59%
90d:
+10.74%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.4/10
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HALO shows positive signals but monitor for confirmation. Market pricing in 2.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HALO shows positive signals but monitor for confirmation. Market pricing in 2.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$135.97
Based on 12.8% avg growth
INTRINSIC VALUE TODAY
$84.42
17.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $69.61, which is considered fair relative to its 30-day fair value range of $67.60 to $70.70. The stock's valuation (Forward PE: 7.0) is in line with its historical norms (7.6). Remarkably, the market is currently pricing in an annual earnings decline of 2.7% over the next few years. This pessimistic expectation contrasts with the company's recent 31.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $67.02, while resistance sits at $72.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.90 (+21.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $67.02, while resistance sits at $72.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.90 (+21.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$67.60 -
$70.70
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.6% below Wall St target ($83.90)
Trading Range Analysis
30-Day Trading Range
$67.60 -
$70.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$67.02
Resistance Level
$72.29
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.97
Wall Street Target
$83.90
(+21.6%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
31.2%
Profit Margin
23.1%
Valuation Discount vs History
-2.7% cheaper
PE vs Historical
7.0 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.7%
(market-implied from PE analysis)
1-Year Target
$67.13
(-3%)
2-Year Target
$65.31
(-5%)
3-Year Target
$63.55
(-8%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$69.26
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 21.5%)
$386.61
(+460%)
Base:
(SPY PE: 7.0, Growth: 21.5%)
$123.79
(+79%)
Bear:
(PE: 5.9, Growth: 21.5%)
$105.22
(+53%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 24.05 | Current EPS (TTM): $2.85
Bull Case
$150.81
(+119%)
Analyst growth 100.0%, PE expands to 26.5
Base Case
$137.10
(+99%)
Market implied 100.0%, PE stable at 24.1
Bear Case
$46.61
(-32%)
Severe decline -20.0%, PE contracts to 20.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.0 to 7.6
Stabilization Target:
$75.18
(+9.0%)
PE Expansion Potential:
+9.0%
Share & Embed Analysis
Last updated: June 23, 2026 10:14 AM ET
Data refreshes hourly during market hours. Next update: 11:14 AM
Data refreshes hourly during market hours. Next update: 11:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Helen Torley
SELL
20000 shares
2026-04-02
Cortney Caudill
SELL
8857 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 69 BUY |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
